Immunomedics, Inc. (IMMU) Director Brian A. Markison Sells 8,390 Shares

Immunomedics, Inc. (NASDAQ:IMMU) Director Brian A. Markison sold 8,390 shares of the company’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $11.89, for a total transaction of $99,757.10. Following the transaction, the director now owns 99,178 shares of the company’s stock, valued at $1,179,226.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Immunomedics, Inc. (IMMU) traded down $0.19 during mid-day trading on Tuesday, reaching $11.39. 2,459,706 shares of the company’s stock traded hands, compared to its average volume of 3,093,523. The company has a quick ratio of 0.74, a current ratio of 0.74 and a debt-to-equity ratio of -0.29. Immunomedics, Inc. has a one year low of $3.01 and a one year high of $14.48.

TRADEMARK VIOLATION WARNING: “Immunomedics, Inc. (IMMU) Director Brian A. Markison Sells 8,390 Shares” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/11/21/immunomedics-inc-immu-director-brian-a-markison-sells-8390-shares.html.

Hedge funds have recently made changes to their positions in the business. Amalgamated Bank boosted its stake in Immunomedics by 8.1% during the second quarter. Amalgamated Bank now owns 12,911 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 966 shares during the period. Stephens Inc. AR purchased a new position in shares of Immunomedics in the second quarter valued at approximately $115,000. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Immunomedics by 11.4% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 1,473 shares during the period. SG Americas Securities LLC boosted its stake in shares of Immunomedics by 99.3% in the second quarter. SG Americas Securities LLC now owns 20,719 shares of the biopharmaceutical company’s stock valued at $183,000 after purchasing an additional 10,323 shares during the period. Finally, Legal & General Group Plc boosted its stake in shares of Immunomedics by 7.4% in the second quarter. Legal & General Group Plc now owns 25,477 shares of the biopharmaceutical company’s stock valued at $222,000 after purchasing an additional 1,747 shares during the period. 62.61% of the stock is owned by institutional investors.

A number of equities analysts have weighed in on the stock. Zacks Investment Research cut shares of Immunomedics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 15th. Jefferies Group LLC set a $11.00 target price on shares of Immunomedics and gave the company a “buy” rating in a research report on Thursday, August 17th. BidaskClub cut shares of Immunomedics from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $15.00 target price on shares of Immunomedics in a research report on Monday, July 24th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Immunomedics presently has a consensus rating of “Buy” and an average target price of $15.33.

About Immunomedics

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply